DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 63,344 shares of the medical device company’s stock after selling 2,700 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in DexCom were worth $4,926,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of DXCM. Blue Whale Capital LLP grew its stake in DexCom by 91.9% in the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after acquiring an additional 113,000 shares during the last quarter. Brooktree Capital Management acquired a new stake in shares of DexCom in the third quarter valued at approximately $683,000. National Pension Service grew its position in shares of DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the last quarter. Intact Investment Management Inc. purchased a new position in shares of DexCom during the 3rd quarter worth approximately $650,000. Finally, Motley Fool Asset Management LLC raised its position in shares of DexCom by 168.7% during the 3rd quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock worth $17,993,000 after purchasing an additional 171,150 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,083 shares of company stock valued at $3,309,794. Company insiders own 0.30% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $88.32 on Wednesday. The company has a market cap of $34.51 billion, a price-to-earnings ratio of 61.76, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The stock’s 50-day moving average is $83.99 and its 200-day moving average is $76.38.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and raised their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Canaccord Genuity Group lifted their price objective on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Citigroup upped their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $99.06.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.